清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA—a retrospective, exploratory cohort study

作者
Chantal A M Bouman,Lieke Tweehuysen,Dieneke Haverkort,Cornelia H. M. van den Ende,Aatke van der Maas,Alfons A den Broeder
出处
期刊:Rheumatology Advances in Practice [Oxford University Press]
卷期号:2 (1): rky008-rky008 被引量:5
标识
DOI:10.1093/rap/rky008
摘要

OBJECTIVES: As data on disease-activity-guided dose optimization of abatacept and tocilizumab are scarce, we explored the feasibility, effectiveness and safety of dose optimization of these biological DMARDs in RA patients in daily practice. METHODS: RA patients who had been treated with abatacept or tocilizumab for ≥6 months, with DAS28 <3.2, were included. Four groups were identified: abatacept dose reduction (DR) and usual care (UC), and tocilizumab DR and UC. Successful DR and discontinuation entailed being on a lower dose than at baseline or having discontinued abatacept or tocilizumab, while maintaining disease activity score with ESR using 28 joint count (DAS28) <3.2. Proportions of patients with successful DR or discontinuation at 12 months were described. Maintenance of DR was investigated using Kaplan-Meier curves. Between-group differences in mean DAS28 and Health assessment questionnaire disability index (HAQ-DI) change (Δ) over 6 and 12 months were estimated. RESULTS: One hundred and nineteen patients were included. DR was attempted in 13 of 28 (46%; 95% CI: 28, 66%) abatacept and 64 of 91 (70%; 95% CI: 60, 79%) tocilizumab patients. At 12 months, 3 of 11 (27%; 95% CI: 6, 61%) abatacept and 20 of 48 (42%; 95% CI: 28, 57%) tocilizumab patients were successfully tapered. One of 11 (9%; 95% CI: 0, 41%) abatacept and 5 of 48 (10%; 95% CI: 3, 23%) tocilizumab patients were successfully discontinued. Mean ΔDAS28 and ΔHAQ-DI at months 6 and 12 were not significantly different between DR and UC. For tocilizumab, DAS28 was significantly higher in the DR compared with the UC group at 6 months. Adverse events were comparable between groups. CONCLUSION: Abatacept and tocilizumab DR appears to be feasible and safe in clinical practice. No benefits in terms of fewer adverse events in the DR group were observed. Furthermore, DR was suboptimal, because all patients were eligible for DR, but in a substantial number of patients no DR was attempted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xuxu213发布了新的文献求助10
1秒前
酷酷的海莲完成签到,获得积分10
2秒前
称心怜菡完成签到,获得积分10
5秒前
369ninja发布了新的文献求助10
11秒前
12秒前
cat发布了新的文献求助10
15秒前
廖道罡完成签到,获得积分10
17秒前
Hello的应助被gyc采纳,获得10
18秒前
Gilgardea发布了新的文献求助10
18秒前
26秒前
听话的尔竹完成签到,获得积分10
27秒前
gyc完成签到,获得积分10
28秒前
独特问梅完成签到,获得积分10
28秒前
gyc发布了新的文献求助10
31秒前
大明完成签到 ,获得积分10
32秒前
科研通AI6.4的应助被cat采纳,获得10
38秒前
Zhangym完成签到 ,获得积分10
48秒前
魔幻雪兰完成签到,获得积分10
48秒前
智者雨人完成签到 ,获得积分10
50秒前
沉默怡完成签到,获得积分10
1分钟前
FashionBoy的应助被朱洪帆采纳,获得10
1分钟前
坚强夜梦完成签到,获得积分10
1分钟前
852的应助被朱洪帆采纳,获得10
1分钟前
1分钟前
solger发布了新的文献求助10
1分钟前
坚定的问芙完成签到,获得积分10
1分钟前
虚心从蓉完成签到,获得积分10
1分钟前
李健的小迷弟的应助被气945采纳,获得10
1分钟前
1分钟前
漂亮的幻枫完成签到,获得积分10
1分钟前
朱洪帆发布了新的文献求助10
1分钟前
2分钟前
369ninja发布了新的文献求助10
2分钟前
威武妙柏完成签到,获得积分10
2分钟前
气945完成签到,获得积分20
2分钟前
气945驳回了李健的应助
2分钟前
Shiyuzz完成签到 ,获得积分10
2分钟前
gzhy完成签到,获得积分10
2分钟前
丰富广缘完成签到,获得积分10
2分钟前
美好傲蕾完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166414
求助须知:如何正确求助?哪些是违规求助? 9559494
关于积分的说明 21750507
捐赠科研通 7757221
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553489
邀请新用户注册赠送积分活动 2473845